Oral Dosage Form New Animal Drugs; Lufenuron Tablets
FederalRegulations
Ask Donna
How this section applies to your facts.
Federal Register › Vol. 60 › 60 FR 362
Text
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 520
Oral Dosage Form New Animal Drugs; Lufenuron Tablets
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect approval of a new animal drug application
(NADA) filed by Ciba Animal Health, Ciba-Geigy Corp. The NADA provides
for oral administration of lufenuron tablets to dogs for the prevention
and control of flea populations.
EFFECTIVE DATE: January 4, 1995.
FOR FURTHER INFORMATION CONTACT: Marcia K. Larkins, Center for
Veterinary Medicine (HFV-112), Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855, 301-594-0614.
SUPPLEMENTARY INFORMATION: Ciba Animal Health, Ciba-Geigy Corp., P.O.
Box 18300, Greensboro, NC 27419-8300, filed NADA 141-035, which
provides for oral administration of Program tablets
containing 45, 90, 204.9, or 409.8 milligrams (mg) of lufenuron per (/)
tablet. Once a month, Program tablets are administered to
dogs, 6 weeks of age and older, at a minimum dosage of 10 mg of
lufenuron/kilogram (4.5 mg/pound) of body weight for the prevention and
control of flea populations. The drug has no deleterious effect on
adult fleas, but it prevents most flea eggs from maturing into adults.
The NADA is approved as of November 23, 1994, and the regulations are
amended in part 520 (21 CFR part 520) by adding new Sec. 520.1288 to
reflect the approval. The basis for approval is discussed in the
freedom of information summary.
In accordance with the freedom of information provisions of part 20
(21 CFR part 20) and Sec. 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a
summary of safety and effectiveness data and information submitted to
support approval of this application may be seen in the Dockets
Management Branch (HFA-305), Food and Drug Administration, rm. 1-23,
12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m.,
Monday through Friday.
Section 512(c)(2)(F)(i) of the Federal Food, Drug, and Cosmetic Act
provides a 5-year period of exclusivity to this original NADA beginning
November 23, 1994, because no active ingredient (including any ester or
salt of the active ingredient) has been approved in any other
application under section 512(b)(1) of the act.
The agency has carefully considered the potential environmental
effects of this action. FDA has concluded that the action will not have
a significant impact on the human environment, and that an
environmental impact statement is not required. The agency's finding of
no significant impact and the evidence supporting that finding,
contained in an environmental assessment, may be seen in the Dockets
Management Branch (address above) between 9 a.m. and 4 p.m., Monday
through Friday.
List of Subjects in 21 CFR Part 520
Animal drugs.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is
amended as follows:
PART 520-ORAL DOSAGE FORM NEW ANIMAL DRUGS
1. The authority citation for 21 CFR part 520 continues to read as
follows:
Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 360b).
2. New Sec. 520.1288 is added to read as follows:
Sec. 520.1288 Lufenuron tablets.
(a) Specifications. Each tablet contains either 45, 90, 204.9, or
409.8 milligrams of lufenuron.
(b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.
(c) Conditions of use--(1) Amount. 10 milligrams of lufenuron per
kilogram (4.5 milligrams per pound) of body weight.
(2) Indications for use. For use in dogs, 6 weeks of age and older,
for the prevention and control of flea populations.
(3) Limitations. Administer tablet(s) after or in conjunction with
a full meal to ensure adequate absorption. Administer tablet(s) once a
month, preferably on same date each time. All dogs in a household
should be treated to achieve maximum efficacy. Because the drug has no
affect on adult fleas, the concurrent use of insecticides that kill
adults may be required depending on the severity of the infestation.
Federal law restricts this drug to use by or on the order of a licensed
veterinarian.
Dated: December 23, 1994.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. 95-164 Filed 1-3-95; 8:45 am]
BILLING CODE 4160-01-F
This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.